TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients
Prof. Frederick Raal (University of Witwatersrand, Johannesburg, South Africa)
Recorded at ISA2015, Amsterdam, The Netherlands on May 24-26, 2015
ISA2015 | Clinical Breakthroughs Based on the TAUSSIG study, a longer term study of treatment with PCSK9 inhibitor evolocumab in a relatively large group of patients with homozygous FH, prof. Frederick Raal concludes that we now have an additional therapy for these difficult to treat patients.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.